Form 4: Esperion Therapeutics Director J. Martin Carroll Receives Significant Equity Grant

Esperion Therapeutics, Inc. Director J. Martin Carroll was granted 33,000 shares of common stock and 44,000 stock options, signaling continued alignment with shareholder interests.

Summary

• J. Martin Carroll, a Director of Esperion Therapeutics, Inc. (ESPR), acquired 33,000 shares of common stock and 44,000 stock options on May 29, 2025.
• The 33,000 shares of common stock were acquired at a price of $0, indicating a grant or award.
• The 44,000 stock options have an exercise price of $0.87 per share and are set to expire on May 29, 2035.
• These equity awards will vest in full on the earlier of May 29, 2026, or the company's next annual meeting of stockholders following May 29, 2025.
• Following these transactions, Mr. Carroll's direct beneficial ownership stands at 97,650 shares of common stock and 44,000 stock options.

Sentiment

Score: 7

Explanation: The grant of common stock and stock options to a director, especially with a vesting schedule, is generally a positive signal, indicating alignment of interests and insider confidence in the company's future. It's an incentive-based award rather than a direct cash investment, but still reflects a positive internal view.

Positives

• The acquisition of 33,000 shares of common stock and 44,000 stock options by a director indicates strong confidence from insider management in the company's future performance.
• The vesting schedule for the awards aligns the director's long-term interests with those of the shareholders, incentivizing sustained value creation.

Future Outlook

The vesting schedule for the equity awards, set to occur by May 29, 2026, or the next annual meeting, implies a forward-looking incentive for the director to contribute to the company's performance over this period.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across publicly traded companies as a form of executive and director compensation, aligning their interests with long-term shareholder value. Such grants are a standard component of compensation packages in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry, similar to companies like Amgen (AMGN) or Gilead Sciences (GILD), to incentivize long-term commitment and performance.
• The structure of the grant, including a mix of common stock and options with a vesting schedule, is typical for aligning director compensation with company performance and retention, mirroring practices seen in other publicly traded life sciences firms.

Corporate Governance

Related Party Transactions

• The acquisition of common stock and stock options by J. Martin Carroll, a director of Esperion Therapeutics, Inc., constitutes a related party transaction as it involves an equity award from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant to a director can be viewed positively as it aligns management's interests with long-term shareholder value creation and may signal insider confidence in the company's future performance.
• Employees: While not directly impacting employees, such compensation structures for leadership can reflect the company's overall approach to incentivizing performance and retaining key talent.

Next Steps

• The acquired common stock and stock options will vest on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.

Key Dates

Recommendation

Keywords

Esperion Therapeutics, ESPR, Form 4, Insider Trading, Stock Grant, Stock Options, Director Compensation, Equity Award, Beneficial Ownership